Enzo Biochem, Inc.

University of Connecticut

St. Jude's Childrens Hospital

Enzo Therapeutics, Inc.

Li, Xiaofeng

Liu, Peng

Zhang, Yazhou

Zhang, Jie

Shan, Jufang

Engelhardt, Dean

Peng Liu

Dean L Engelhardt

Xiaofeng Li

Zenon D Konteatis

Dianqing Wu

Yazhou Zhang

Jie Zheng

Samuel K Reznik

Jie Zhang

Jufang Shan

Wenzhong Liu

Dean Engelhardt

Jeremy M Travins

Zhihua Sui

Shubao Zhou

Matthew Medeiros

Guangning Ma

Mingzong Li

The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.

Compositions and methods for bone formation and remodeling

Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and/or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.

Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells

Growing community of inventors

West Hartford, CT, United States of America

Peng Liu